| Recruiting | A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safet Marburg Virus Disease | Phase 1 | 2026-03-27 |
| Recruiting | Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and i HIV Infections | Phase 1 | 2025-12-15 |
| Recruiting | A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Wit HIV | Phase 1 | 2025-07-28 |
| Recruiting | A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Tuberculosis (TB) | Phase 2 | 2025-02-19 |
| Withdrawn | Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living with HIV (PLWH) in Africa HIV | EARLY_Phase 1 | 2024-08-27 |
| Enrolling By Invitation | A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvante Hiv | Phase 1 | 2024-04-16 |
| Recruiting | A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa Lassa Fever | Phase 2 | 2024-03-06 |
| Completed | Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health Ebola Sudan Virus Disease | Phase 1 | 2023-06-19 |
| Unknown | A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate Hiv | Phase 1 | 2023-06-01 |
| Unknown | A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) HIV-1-infection | Phase 1 | 2022-05-25 |
| Active Not Recruiting | A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g Hiv | Phase 1 | 2021-11-12 |
| Unknown | A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good Genera Lassa Fever, Lassa Virus Infection | Phase 1 | 2021-06-23 |
| Completed | A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.G HIV Infections | Phase 1 | 2020-08-01 |
| Completed | Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence Tuberculosis, Pulmonary | Phase 2 | 2019-01-31 |
| Completed | Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, HIV-1-infection | Phase 1 / Phase 2 | 2019-01-25 |
| Completed | A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safet HIV Infections | Phase 1 | 2018-12-03 |
| Completed | A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infecte HIV/AIDS | Phase 1 / Phase 2 | 2018-12-03 |
| Completed | A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted HIV/AIDS | Phase 1 | 2018-06-15 |
| Completed | MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa Tuberculosis | Phase 1 / Phase 2 | 2018-05-14 |
| Completed | A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfect HIV Infections | Phase 1 | 2017-10-23 |
| Completed | Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults HIV Infection | Phase 1 | 2016-11-01 |
| Completed | Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine HIV | Phase 1 | 2015-01-01 |
| Unknown | A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Ant HIV Infections | Phase 1 | 2014-09-01 |
| Completed | Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine G HIV Infections | Phase 1 | 2013-03-01 |
| Completed | Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers HIV Infections | Phase 1 | 2011-12-01 |
| Completed | Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines HIV Infections | Phase 1 | 2011-02-01 |
| Completed | Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults HIV Infections | Phase 1 | 2010-10-01 |
| Completed | A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk P HIV Infections | Phase 1 / Phase 2 | 2009-10-01 |
| Completed | A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk P HIV Infection | Phase 1 / Phase 2 | 2009-10-01 |
| Completed | A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers HIV, HIV Infections | Phase 1 | 2009-03-01 |
| Completed | Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Va HIV Infections | Phase 1 | 2008-11-01 |
| Completed | Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid Human Immunodeficiency Virus Infections, HIV Infections | Phase 2 | 2005-10-01 |
| Completed | Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults HIV Infection | Phase 1 | 2005-01-01 |
| Completed | Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults HIV Infection | Phase 1 | 2003-12-01 |
| Completed | Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine HIV Infection | Phase 1 | 2003-12-01 |
| Completed | A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Va HIV Infections | Phase 2 | 2003-04-01 |